Bank of America
-
-
DCM bankers hope that Mexican lender Nafin’s planned green bond could be the first of many from the country, and that other development banks in Latin America will follow Mexico’s model.
-
Poste Italiane, the Italian state-owned post office, looks set to raise €3.058bn in its IPO, which has been completed against an uneasy market backdrop. Final pricing has not yet been announced, but looks highly likely to be €6.75 a share. -
Teva, the New York-listed Israeli pharmaceutical company, held a meeting with banks on Wednesday for the syndication of $33.75bn of loans to buy generic drug business Allergan Generics.
-
The UK Debt Management Office built its largest ever order book for a syndicated bond on Tuesday, but bankers away from the deal felt it was the trade’s timing that was particularly impressive.
-
Abengoa, the Spanish renewable energy company, suffered yet another unsteady trading session on Thursday over revelations in a leaked KPMG report of a €250m cash deficit.
-
A struggling nuevo sol is turning Peru’s companies rapidly away from international bond markets as the issuer of the tightest Peruvian corporate bond ever looks to rid itself of all dollar exposure.
-
Poste Italiane, the Italian state-owned post office, narrowed on Wednesday the price range of its initial public offering in Milan. The bookbuild is set to close on Thursday.
-
Government-owned development bank Nacional Financiera (Nafin) is plotting what would be the first ever green bond from Mexico and — unlike the previous two such bonds from LatAm — will be ringfencing the proceeds.
-
Deezer and Showroomprive, two French websites, though of very different kinds, are seeking to attract demand for their respective initial public offerings.
-
The UK Debt Management Office built its largest ever order book for a syndicated bond on Tuesday, when it printed a deal with the longest duration in its conventional Gilt portfolio.
-
Teva, the Israeli pharmaceutical company, will hold a meeting with banks on Wednesday for the syndication of $33.75bn of loans it is using to buy generic drug business Allergan Generics.
